NLS

CHOSA Oncology has established a business presence in Boston, Massachusetts, marking an important strategic step in the company's US commercialization for Platin-DRP.

Cantargia has reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and therefore at risk of developing lung cancer.

Global Health EDCTP3 and the Novo Nordisk Foundation have announced a funding partnership to support research aimed at improving health outcomes in Africa and strengthening global health innovation, with the Novo Nordisk Foundation contributing up to EUR 18 million to the initiative.

Alvotech has announced the pricing of its previously announced underwritten public offering of 22,666,667 of its ordinary shares at an offering price of USD 3.75 per share.

Abera Bioscience has announces that CEPI (Coalition for Epidemic Preparedness Innovations) has decided to extend the ongoing project supporting the development of Abera’s BERA vaccine platform and the company’s innovative influenza vaccine candidate. 

SynAct Pharma has reported that resomelagon in combination with methotrexate showed promising clinical effects on par with previous findings with ACR20 reaching 76,4% in the most effective dose compared to 60,8% in the placebo treated control group reaching statistical significance in the subset of patients entering the study with ACR/EULAR class II-III disease.